Company intelligence / Profile preview

PNP Therapeutics

Birmingham, Alabama, United Statespnptherapeutics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company’s lead program, Gedeptin®, progressed through Phase I clinical trials targeting cancer. Orphan Drug Status was granted for the product. As of September 2021, all rights and development responsibilities were transferred to GeoVax via exclusive license.

Therapeutic areas: Oncology
Modalities: Gene therapy/enzyme prodrug therapy (using E. coli purine nucleoside phosphorylase with a prodrug system)
Industry: Biotech

Drug pipeline

1 asset

PNP-DOX

Preclinical

Partnerships

Exclusive licensing partnership with GeoVax Labs, Inc.

Beyond the preview

Go deeper on PNP Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PNP Therapeutics.